Curate Biosciences Appoints Daniel Getts, Ph.D. to its Board of Directors
CARLSBAD, Calif., Aug. 15, 2022 /PRNewswire/ -- Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Daniel Getts, Ph.D., cofounder and CEO of Myeloid Therapeutics, has been appointed to its Board of Directors. Dr. Getts is an immunologist by training and a serial entrepreneur with a proven track record in building and financing companies focused on creating next-generation immunotherapies. Dr. Getts will provide strategic guidance to Curate Biosciences as it approaches commercialization of its transformational CurateĀ® Cell Processing system, fulfilling its commitment to deliver technologies that ensure faster, better, and more cost-effective access to cell therapies for patients.
- CARLSBAD, Calif., Aug. 15, 2022 /PRNewswire/ -- Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Daniel Getts, Ph.D., cofounder and CEO of Myeloid Therapeutics, has been appointed to its Board of Directors.
- Daniel brings with him a deep understanding of the cell therapy space, with significant experience in translational science, operational leadership and commercial acumen," said Mike Grisham, CEO of Curate Biosciences.
- "His breadth and depth of expertise will strengthen our Board and will be invaluable as we bring our life-saving Curate Platform to patients."
- Dr. Getts commented, "I am thrilled to join the Board of Curate Biosciences, who share a vision to innovate the cell therapy field.